POLE2 promotes osteosarcoma progression by enhancing the stability of CD44

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents.
• There is an urgent need for novel therapeutic strategies for OS.
• Gene expression profiling can identify potential therapeutic targets.

Purpose of the Study:

• To identify novel therapeutic targets for osteosarcoma (OS).
• To investigate the role of DNA polymerase epsilon 2 (POLE2) in OS progression.
• To elucidate the molecular mechanisms by which POLE2 influences OS.

Main Methods:

• Differential gene expression analysis using the GSE14359 dataset.
• Validation of POLE2 overexpression via immunohistochemistry, qPCR, and Western blot.
• In vitro and in vivo functional assays following POLE2 knockdown.
• Bioinformatics analysis to identify downstream targets and pathways.

Main Results:

• POLE2 was significantly overexpressed in OS tissues and cell lines.
• POLE2 knockdown inhibited OS cell proliferation, migration, and tumor growth, while increasing apoptosis.
• POLE2 targets CD44 and the Rac signaling pathway, reducing CD44 ubiquitination via MDM2.
• CD44 knockdown counteracted the tumor-promoting effects of POLE2 overexpression.

Conclusions:

• POLE2 promotes OS progression by upregulating CD44 expression through inhibition of MDM2-mediated ubiquitination.
• The POLE2/CD44 axis activates the Rac signaling pathway, contributing to OS development.
• POLE2 and CD44 represent promising therapeutic targets for osteosarcoma treatment.